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Edited by Frances ShannonAbstract To characterize the regulation of lymphoid Aiolos
transcription factor, we have cloned its promoter. Full promoter
and nested deletions were expressed in lymphoid and non-lym-
phoid cell lines. The minimal promoter activity could be consid-
ered as a 172 bp upstream from the ATG for Jurkat and
HEK293 cells and as a 370 bp fragment for U937 cells. More-
over, we have mapped the transcription initiation site. Retarda-
tion gels showed binding activity for Ikaros, NFjB and AP4
transcription factors and mutations in their binding sites abolish
Aiolos promoter activity. Chromatin immunoprecipitation assay
revealed that Ikaros, NFjB and AP4 are bound to Aiolos pro-
moter. The important function of Ikaros and NFjB is underlined
by their over expression, which results in the trans-activation of
the promoter and drives Aiolos expression in cell lines and in
freshly isolated B and T cells, while over expression of a domi-
nant negative Ikaros isoform is able to block Aiolos expression.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Aiolos; Ikaros; Transcription factor; Promoter;
NFjB1. Introduction
The regulation of gene expression is required for the progres-
sive restriction of a pluripotent hematopoietic stem cell to one
of the various lineages and it may be mediated, in part, by nu-
clear transcription factors. A candidate is Ikaros, a family of
zinc ﬁnger DNA-binding proteins known to be a master regu-
lator of lymphocyte diﬀerentiation [1,2]. Aiolos is a lymphoid
transcription factor that was identiﬁed as an homologue of
the largest Ikaros isoform with similarities in the DNA bind-
ing, activation and dimerization domains [3].
Aiolos is not present in primitive hematopoietic populations
and is ﬁrst detected at low levels in pro-B and double negative
CD4/CD8 thymocyte precursors and is up-regulated as these
cells progress to the pre-B and double positive CD4/CD8*Corresponding author. Address: Immunologie Cellulaire et Tissulaire,
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doi:10.1016/j.febslet.2007.03.025stages of diﬀerentiation [4]. Aiolos is expressed in mature
peripheral B cells, but not signiﬁcantly in splenic cells [1,2,4].
The physiological eﬀect of Aiolos gene inactivation in knock
out mice is an increase in B cell precursors, a spontaneous pro-
duction of autoantibodies and the development of B cell lym-
phomas. In contrast, peritoneal, marginal and recirculating B
cells are severely depleted [4]. This phenotype is consistent with
a diminution of the activation threshold through B-cell antigen
receptor. Finally, T cell development in Aiolos null mice is rel-
atively unaﬀected.
The Aiolos transcription factor has been reported to
control T cell death by regulating the expression of Bcl-2 [5],
suggesting the possibility that evasion of apoptotic cell death
is a common mechanism by which Ikaros family proteins par-
ticipate in leukemogenesis. It has also been shown that the
association of Aiolos and the anti-apoptotic molecule Bcl-x
is involved in the control of apoptosis via IL-4 receptor signal-
ling [6].
Both Ikaros and Aiolos can activate reporter genes
expressed under the control of a promoter with binding sites
for these transcription factors [1,7,8]. Binding sequences for
Ikaros proteins were also found in the promoters of both
CD4 and CD2 genes, and in the promoters for genes encoding
the early pre-B cell diﬀerentiation antigen mb-1, IL-2Ra,
PRDII element of the b interferon gene, the anti-apoptotic
protein Bcl-2 and in the enhancer of the H-2kb gene, as well
as in the E-Ad promoter [5,9–20]. Moreover, it has been shown
that the k 5 gene is a target for repression by Ikaros, acting on
a binding site located in the k 5 promoter through a mecha-
nism that does not require heterochromatin relocation [21].
The ﬁnding that mutation of a single binding site in the k 5
promoter causes loss of repression suggest a direct repressive
eﬀect of Ikaros binding on the promoter.
Several studies provide evidence that Ikaros splice variants
are translated to protein isoforms with alternate functional
and structural properties. These isoforms are through to have
a dominant negative function because they prevent binding of
the dimer to the DNA [22–27]. Contrary to the mouse, ﬁve
human Aiolos isoforms have been reported, including domi-
nant negative variants with less than three DNA-binding do-
mains [24]. It is therefore possible that stoichiometric
alterations or functional disequilibrium between putative
oncogenic and antioncogenic Aiolos isoforms may play a role
in pathogenesis of B cell malignancies.
We present here the cloning and characterization of the hu-
man Aiolos promoter. We have delineated a positive regula-
tory region important for the promoter activity of the Aiolosblished by Elsevier B.V. All rights reserved.
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AP4-binding sites are critical for Aiolos promoter activity
in vitro and in vivo. Mutation or their binding sites abrogates
promoter activity and ﬁnally, overexpression of Ikaros and
NFjB is able to activate the promoter resulting in Aiolos
expression in cell lines as well as in freshly isolated T and B
cells.2. Materials and methods
2.1. Cell lines and cell culture
Daudi (human Burkitt’s lymphoma), U937 (human hystiocytic lym-
phoma), Jurkat (human T lymphocyte acute leukemia) and HEK293
(human embryonic kidney) cell lines were used in this study. Daudi,
Jurkat and U937 were cultured in RPMI supplemented with 10%
heat-inactivated foetal calf serum, 2 mM glutamine, 10 mM HEPES.
HEK293 cell line was cultured in DMEM supplemented with 10%
heat-inactivated foetal calf serum, 10 mM HEPES, 2 mM glutamine.
T and B cells, as well as monocytes, have been freshly isolated from
blood. Spleen and liver tissues were obtained from Hoˆpital Pitie´-Salpeˆ-
trie`re.
2.2. Reagents, antibodies and plasmids
Anti-CD3, anti-CD14 and anti-CD19 magnetic beads and B and T
cell negative isolation kits were from Dynal (Oslo, Norway). 5 0
RACE-PCR system for rapid cDNA ampliﬁcation and Advantage 2
PCR kit were purchased from BD Biosciences (Palo Alto, CA).
Quick-change site-directed mutagenesis kit was from Stratagene (La
Jolla, CA). The pGL3 basic and pRL-CMV vectors as well as the dual
luciferase reporter assay kit were purchased from Promega (Madison,
WI). Human T and B Nucleofactor kits were from Amaxa (Gaither-
burg, MD). Anti-Ikaros and anti-AP4 antibodies were from Santa
Cruz (Santa Cruz, CA). Anti-Aiolos antibody was generated in our
lab as previously described [5]. Anti-NFjB antibody was from BD Bio-
sciences (San Jose, CA) and anti-histone antibody was from Chemicon
International (Temecula, CA).
2.3. Bioinformatic analysis
Aiolos promoter was identiﬁed using a comparative genomic
approach and the Genomatix software tool. Transcription binding
sites sequence analyses were conducted using MatInspector Profes-
sional program (Genomatix Software, Germany).
2.4. Cloning, sequencing and mutagenesis of the Aiolos promoter
Based on the published sequence of human chromosome 17, a 3.9 kb
fragment spanning 3956 nucleotides of human Aiolos promoter was
obtained by PCR using as template genomic DNA from peripheral
blood mononuclear cells.
The resulting fragment was cloned into the pCRII-Topo vector
using the TOPO-TA cloning kit. The pTopo-3.9 was then used as a
PCR template to generate the following deletion constructs: pTopo-
1.5 kb, pTopo-1.1 kb, pTopo-920 bp, pTopo-670 bp, pTopo-370 bp,
pTopo-175 bp and pTopo-92 bp. The deletion fragments were cloned
into the pGL3 basic luciferase reporter vector. Site-directed mutagen-
esis of the ATG translation initiation site and potential binding sites
for Ikaros, NFjB and AP4 were performed using the Quick Change
site-directed mutagenesis kit.
2.5. Transient transfection and luciferase assay
Jurkat, U937 and HEK 293 cells were transiently transfected using
lipofectamine 2000 reagent. Daudi cells were transfected by electropor-
ation. Cells were cotransfected with diﬀerent fragments of Aiolos pro-
moter and pRL, containing the renillase reporter gene as an internal
control. Transfection of Ikaros and NFjB in Jurkat and U937 cells
was done using cell line Nucleofactor kit, according to the manufac-
turer’s instructions. Daudi was transfected using DEAE-dextran.
Luciferase assay was performed according to the manufacturer’s pro-
tocol. Finally, freshly isolated T or B cells were transfected using the
Human T or B cell Nucleofactor kit.2.6. Western blot analysis
Western blot was performed as previously described [5].
2.7. Radioactive end labelling
Oligonucleotides containing binding sites for the NFjB, AP4 and
Ikaros transcription factors were synthesized with the addition of
ATTA at the 5 0 termini to allow radiolabelling, after annealing, by
Klenow ﬁll-in reaction using 32P-cdATP.
2.8. Nuclear extracts and electrophoretic mobility shift assay (EMSA)
and supershift
Nuclear extracts, EMSA and supershift were made as previously de-
scribed [5].
2.9. Chromatin immunoprecipitation
Quantiﬁcation of chromatin immunoprecipitated (ChIP) DNA frag-
ments was carried out on an ABI PRISM 7300 sequence detection
system using SYBR green according to standard protocols. Primers
were designed with PrimerExpress 2.0 software (Applied Biosystems)
and were used at a ﬁnal concentration of 600 nm each. The speciﬁc pri-
mer set matches the proximal promoter of Aiolos, whereas reference
primers match a sequence upstream of Aiolos’ 3 0-end. Primers were cal-
ibrated with serial dilutions of input DNA from the same chromatin
batch also used for ChIP. Relative fold in vivo enrichment of DNA
fragments was calculated determining the ratio of ChIPpromoter/
ChIP3 0-end and non-speciﬁc background enrichment was deﬁned as 1-
fold enrichment. All reactions were run in triplicate and included no
template controls.
2.10. Human monocytes, B and T cells isolation
After Ficoll-Hypaque mononuclear cell separation, we obtained spe-
ciﬁc lineages by positive or negative selection, depending on further
use. For RACE-PCR, we isolated monocytes, T and B cells using
anti-CD14, anti-CD3 or anti-CD19 Dynal magnetic beads, respec-
tively, according to the manufacturer’s instructions. For transfection
of Ikaros and NFjB in B cells, we made negative sorting with Dynal
B or T cells Negative isolation kit.
2.11. RACE-PCR analysis and transcription start site mapping
We mapped the transcription start site using the 5 0 RACE system for
rapid ampliﬁcation of cDNA ends, according to the procedure de-
scribed by the manufacturer. PCR fragments were puriﬁed and cloned
into a pTOPO TA vector.
2.12. RT-PCR and RT-qPCR analysis
Total RNA was ﬁrst puriﬁed using the RNAeasy kit and oligo(dT)-
primed ﬁrst strand cDNA were synthesised using Superscript II reverse
transcriptase. Quantitative PCR was carried out on an ABI PRISM
7700 detection system. We used pre-developed TaqMan assay reagents
(primer and probes) for detection of human Aiolos and the absolute
qPCR Rox mix, according to the manufacturers’ instructions.3. Results
3.1. Structure of the human Aiolos gene
To characterize the regulation of the gene encoding Aiolos,
we have isolated, sequenced and characterized its promoter.
Analysis of the chromosomal region 17q21 allowed us to delin-
eate the putative promoter region of Aiolos. Fig. 1A shows the
structure of Aiolos gene with 8 exons and the promoter region
upstream of the ATG initiation codon. We screened by PCR a
human genomic DNA from peripheral blood mononuclear
cells using oligonucleotides speciﬁc for the 5 0 untranslated re-
gion and the ATG region of Aiolos (for primers, see support-
ing information). We isolated a clone containing a 3.9 kb
fragment including the initiation codon, which was subse-
quently mutated in order to avoid transcription of luciferase
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Fig. 1. Aiolos gene structure and its promoter region. (A) Human Aiolos gene is located on chromosome 17 and is composed by eight exons. The size
of the diﬀerent exons, as well as the promoter upstream of the ATG is shown. (B) The nucleotide sequence of 377 bp of the 5 0 ﬂanking region of the
Aiolos gene is shown. The ATG codon is in bold type. The old and the new transcription initiation site (TIS) are labelled with a star. The Ikaros,
AP4-1, AP4-2, NFjB1 and NFjB2 binding sites are in bold and underlined. Other hypothetical binding sites in the promoter are shown. The CpG
island is in grey. The minimal Aiolos promoter is doted. (C) Four diﬀerent cell lines representative of lymphoid and non-lymphoid (Daudi, Jurkat,
U937 and HEK293) were analyzed for Aiolos expression at the RNA level by RT-qPCR and at the protein level by western blot. Anti-histones
antibody and HPRT were used as internal control.
A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616 1607gene from the Aiolos ATG. Sequence analysis of this fragment
showed that it contains precisely 3927 bp. Fig. 1B shows
377 bp upstream from the ATG, which correspond to the
CpG island of Aiolos promoter.
Analysis of this DNA sequence using the Mat Inspector soft-
ware showed, among others, potential binding sites for the
NFjB, Ikaros, p53, BARB and AP4 transcription factors.No TATA or CAAT box could be identiﬁed although a
CpG island was detected (Fig. 1B). For the functional analysis
of Aiolos promoter, four diﬀerent cell lines representative of
lymphoid and non-lymphoid lineages, with diﬀerent Aiolos
expression level, were transfected with the luciferase expression
vector constructs. First, Aiolos expression was tested in the dif-
ferent cell lines at the RNA and protein level (Fig. 1C). U937
1608 A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616(promonocyte) cells are negative for Aiolos expression, in our
experimental conditions, at both RNA and protein level, as de-
tected by quantitative RT-PCR and by western blot, while
HEK293 (embryonic kidney) cells are positive for Aiolos
expression at the RNA, but not at the protein level. Finally,
Jurkat (T cell line) and Daudi (B cell line) cells are positive
for Aiolos expression, at the RNA and protein levels (Fig. 1C).
In addition, we mapped the transcription initiation site using
the SMART RACE cDNA ampliﬁcation method. RNA from
liver, spleen, as well as from diﬀerent cell lines was used as tem-
plate. RACE-PCR analysis was performed using an oligonu-
cleotide derived from the coding region and an adapter
primer provided with the Kit (for oligonucleotides, see Table
1, supplementary data). An extended cDNA was ampliﬁed
using universal primer and Aiolos-exon IV primer (Fig. 2A).
The speciﬁc PCR product was cloned and sequenced, resulting
in a fragment of 392 bp observed in Daudi, Jurkat, HEK293
and spleen. No PCR product was detected in U937 and liver
(Fig. 2B). The RT-PCR conﬁrmed the transcription initiation
site observed by RACE-PCR (Fig. 2B). To corroborate that in
freshly isolated human cells the transcription initiation site was
identical to that found in cell lines, we made a RT-PCR using
RNA from freshly isolated human T and B cells as well asTable 1
Oligonucleotides used in this study
RACE-PCR
Aiolos-IV-R 5 0-AGGCTCTTCTGCATTTCCCA-30
RT-PCR
Aiolos-I-F 5 0-CGGCAGCGACATGGAAG-30
Aiolos-II-R 5 0-CACAGACTGCTCCTGAGTGC-30
Aiolos-VIII-R 5 0-TAGCTGATGGCGTTATTGATGG-30
PBGD-F 5 0-CTGGTAACGGCAATGCGGCT-30
PBGD-R 5 0-GCAGATGGCTCCGATGGTGA-30
Cloning and nested deletions
3940-F 5 0-CGGAAGGCAGGAAGAGAATAAAGGAAAA-3 0
1575-F 5 0-ATCCTCATACCATCCCTGTGAAAT-30
1170-F 5 0-ATATGGACAGCTGATGCACAAACC-30
920-F 5 0-GGGTGTTGGGAGAAGATGTTGACT-30
670-F 5 0-GTGCCAAAATCCTTTCCAACTGTC-30
370-F 5 0-CCTCCGTGTGATGTCACTTTTCTC-30
175-F 5 0-GGCTCCTGCCCTTTTCAGTCT-30
92-F 5 0-ATTAGCTAGCTGAGTCCAGGCGACGGCAGGA-3 0
Aio (AT*G)-R 5 0-CTGGAGGCTCACCTTCCTTGTC-30
Mutagenesis
AP4-1-F 5 0-GAGTAGCCACAGCGGCATCTCCAGCC-
CGGCCCGGCAG-30
AP4-2-F 5 0-AATCTCCCGCCATATGCGCGCTGAGTC-30
NFjB2-F 5 0-CTGCCGGATCCCGATAACTCCCCGCG-30
Ikaros-F 5 0-GACTCCCCGCGCCGGGTGTTTCCCGCCAGCTGC-30
NFjB/Ikaros-F 5 0-GACTCCCCGCGCCGGAGATCTCCCGCCAGCTGC-30
EMSA
AP4-F 5 0-ATTACACAGCGGCAGCTCCAGCCCGG-30
Ikaros-F 5 0-ATTACCGCGCCGGGAATCTCCCGCCA-30
NFjB-F 5 0-ATTACCGGATCCCGGGGACTCCCCGC-30
AP4-m-F 5 0-ATTACACAGCGGATATTCCAGCCCGG-30
Ikaros-m-F 5 0-ATTACCGCGCCGAATTTCTCCCGCCA-30
NFjB-m-F 5 0-ATTACCGGATCCCATAACTCCCCGC-3 0
ChIP
Aio-5 0-F 5 0-CCTTTCGAATGTCAAACCCAAG-30
Aio-5 0-R 5 0-GATGCGACATTTCCATCCTGT-30
Aio-3 0-F 5 0-TGTGCACTTGTTGTCCCAGTACT-30
Aio-3 0-R 5 0-CAGGTGATCCTCCCACCTCA-30monocytes (Fig. 2B). No PCR product was observed in mono-
cytes. Our results show that TIS is located 153 bp upstream of
the ATG (Fig. 2C).
3.2. Identiﬁcation of Aiolos minimal promoter region
We cloned the 3.9 kb fragment, in a -sense orientation, in
front of the luciferase reporter gene present in the pGL3 basic
vector and the enzymatic activity was measured using the dual
luciferase reporter assay (luciferase and renillase) system. Sup-
porting information schematically shows the full-length Aiolos
promoter and the diﬀerent 5 0 nested deletion promoter-lucifer-
ase constructs used in this study (Table 2).
The full-length Aiolos promoter, pGL3-3940, shows lucifer-
ase activity in Jurkat, Daudi, U937 and HEK cells after tran-
sient transfection, although the level of enzymatic activity was
diﬀerent among the cell lines tested (Fig. 3). To delineate the
regulatory elements in the cloned Aiolos promoter, as well as
the minimal promoter, we examined the nested 5 0 deletions
of Aiolos promoter luciferase constructs generated by PCR.
Deleted promoter constructs were transfected in the mentioned
cell lines.
Deletion of 2465 bp (pGL3-1575) did not modify the lucifer-
ase activity compared to the level of the full-length promoter
activity in transfected Jurkat cells. Moderate decrease of the
enzymatic activity was detected in deletions comprised be-
tween pGL3-1170 and pGL3-670. Luciferase activity was
strongly increased in the pGL3-175 deletion construct, suggest-
ing the presence of negative regulatory elements (Fig. 3). Final-
ly, no luciferase activity was detected after transfection in
Jurkat cells with pGL3-92.
Promoter constructs harbouring nested deletions were also
transfected into the Daudi cell line (Fig. 3). All transfected
constructs, except pGL3-92, displayed luciferase activity
although the pGL3-175 and pGL3-920 showed lower enzy-
matic activity compared to the full-length promoter construct,
suggesting again the presence of negative regulatory elements.
Deletions of Aiolos promoter were transfected into the
promonocytic cell line U937, which does not express Aiolos
(Fig. 3). The enzymatic activity of the deletions was reduced,
compared to the full-length promoter, with a signiﬁcant in-
crease of luciferase activity in pGL3-175. This result suggests
a potential inhibitory region upstream of 3.9 kb in the endog-
enous Aiolos promoter. No luciferase activity was detected in
U937 cell after transfection of pGL3-92.
When the nested promoter deletions were transfected in
HEK293 cells (Fig. 3), we observed that deletions comprised
between pGL3-1575 and pGL3-370 did not signiﬁcantly mod-
ify the luciferase activity compared to the full-length promoter.
No luciferase activity was detected in HEK293 cells upon
transfection of the pGL3-92 promoter deletion and the highest
luciferase activity was detected upon transfection of the pGL3-
175 construct. Statistical analyses are shown to demonstrate
the signiﬁcance of the diﬀerences. Comparison of pGL3-92
versus pGL3-basic vector did not show signiﬁcant diﬀerences.
Taken together, these results allow us to delineate the mini-
mum region with promoter activity, located between the
ATG and the 175 bp for Jurkat and HEK293 cell lines and
a minimum promoter located between the ATG and 370 bp
for Daudi cells. For U937, the highest promoter activity is de-
tected using the total cloned promoter. These results also high-
light the presence of putative negative regulatory elements in
the Aiolos promoter, since promoter activity is signiﬁcantly
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Fig. 2. Determination of the transcription initiation site (TIS). (A) Schematic representation of the approach used to map the transcription initiation
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Table 2
Summary of 5 0 nested Aiolos promoter deletions
Aiolos promoter constructs Size of the promoter insert (bp)
pGL3-3940 3927
pGL3-1575 1562
pGL3-1170 1157
pGL3-920 907
pGL3-670 657
pGL3-370 357
GL3-175 162
pGL3-92 79
pGL3-basic 0
A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616 1609increased by deletion of some of its regions. In addition, these
results also suggest that, independently of the cell line used, the
full-length promoter, as well as the deletions show promoter
activity.
3.3. Characterization of the proteins binding to Aiolos
minimal promoter
Since the pGL3-175 deletion appears to be the shortest frag-
ment with promoter activity and since additional deletions of
this fragment did not show luciferase activity, we focusedour attention on the identiﬁcation of putative binding sites
for transcription factors in this promoter fragment. Fig. 4A
shows the predicted binding sites detected in pGL3-175 pro-
moter deletion: two binding sites for the transcription factor
NFjB, one binding site for Ikaros and two binding sites for
AP4. The presence of binding sites for AP4, NFjB and Ikaros
in the promoter suggests that these proteins might be involved
in the regulation of Aiolos transcription. On this basis, we ana-
lyze whether cells used in this study expressed these proteins.
For this purpose, we isolated nuclear proteins from Daudi,
Jurkat, U937 and HEK293 and analyzed the expression of Ika-
ros, NFjB and AP4 by western blot. As shown in Fig. 4B, all
cell lines tested express at similar level NFjB and AP4 tran-
scription factors. Ikaros was abundantly expressed in Daudi
and Jurkat cells, while U937 and HEK cells expressed lower
level of the protein.
To test if DNA-binding forms of Ikaros, AP4 and NFjB
were present in Daudi, Jurkat, U937 or HEK293 cells, we per-
formed electrophoretic mobility shift assay (EMSA) and com-
petition using double-stranded oligonucleotides corresponding
to the identiﬁed NFjB, AP4 and Ikaros-binding sites. We de-
tected protein-binding activity to Ikaros oligonucleotides when
using nuclear extracts from Daudi, Jurkat, U937 and HEK293
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1610 A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616cells (Fig. 4C). In the case of Jurkat and U937 extracts, two re-
tarded DNA–protein complexes were observed. The retarded
bands were speciﬁc since excess of unlabelled Ikaros oligonu-
cleotides inhibited formation of the complex (Fig. 4C). Simi-
larly, we also detected protein-binding activity to NFjB
oligonucleotides when using nuclear extracts from Daudi, Jur-
kat, U937 and HEK293 (Fig. 4C). The same result was ob-
served when using AP4 oligonucleotides (Fig. 4C). The
NFjB and AP4 complex formed were speciﬁc since an excess
of unlabelled NFjB and AP4 was able to inhibit the formation
of complex. These results were also conﬁrmed by supershift
using speciﬁc antibodies in order to identify these bands as spe-
ciﬁc proteins. As shown in Fig. 4B, we observed a supershift of
the bands using antibodies against NFjB, AP4 and Ikaros.
To corroborate the role of Ikaros-, NFjB- and AP4-binding
sites, we generated oligonucleotides harbouring mutated bind-
ing sites for these transcription factors and we were unable to
detect protein binding activity when using nuclear extracts
from Daudi, Jurkat, U937 and HEK293 cells (Fig. 4C). The
data suggest that AP4, Ikaros and NFjB transcription factorsmay be responsible for the transactivation of the Aiolos pro-
moter.
To further evaluate the functional role of NFjB, AP4 and
Ikaros transcription factors in the control of Aiolos promoter
activity, we mutated the corresponding binding sites in the
Aiolos promoter (Fig. 5A). We transiently transfected these
mutated constructs in Daudi, Jurkat, U937 and HEK293 cells
and analyzed the luciferase activity. Fig. 5B shows mutation of
the NFjB2-binding sites in Aiolos promoter signiﬁcantly re-
duces luciferase activity in Jurkat (70%), Daudi (24%) and
HEK293 (100%) compared to pGL3-175 control (Fig. 5B).
Mutation of the AP4-1 and AP4-2-binding sites in the Aiolos
promoter also reduced luciferase activity in Jurkat (48% and
45%, respectively), Daudi (56% and 71%, respectively), U937
(71% and 65%, respectively) and HEK293 (23% and 88%,
respectively) compared to pGL3-175 control (Fig. 5B). Muta-
tion of the Ikaros/NFjB-binding site in Aiolos promoter re-
duces luciferase activity in Jurkat (16%), Daudi (65%), U937
(51%) and HEK293 (15%) cell lines, compared to pGL3-175
control. Mutation of the Ikaros-binding site reduces luciferase
activity in Jurkat (43%), Daudi (50%), U937 (71%) and
HEK293 (40%). Finally, mutation of the Ikaros/AP4/NFjB-
binding sites in Aiolos promoter reduces luciferase activity in
Jurkat (61%), Daudi (56%), U937 (72%) and HEK293 (74%).
Statistical analysis is shown to demonstrate the signiﬁcance
of the diﬀerences. Comparison of pGL3-92 versus pGL3-basic
did not show signiﬁcant diﬀerences. These results suggest that
AP4, Ikaros and NFjB transcription factors contribute to
Aiolos promoter transactivation.
3.4. Binding of Ikaros, AP4 and NFjB to Aiolos regulatory
elements in vivo
To investigate whether Aiolos transcription is directly con-
trolled by Ikaros, NFjB and AP4, in vivo, we performed chro-
matin immunoprecipitation (ChIP) assays to determine if these
transcription factors are physically bound to the Aiolos pro-
moter. Using an antibody against Ikaros we obtained a signif-
icant enrichment in Jurkat and Daudi cells (Fig. 6). The use of
an antibody against NFjB showed a moderate enrichment in
Daudi cells whereas no enrichment was observed in Jurkat,
HEK293 and U937 (Fig. 6). Finally, an anti-AP4 antibody
showed a moderate enrichment in Jurkat cells. These results
indicate that Ikaros speciﬁcally bind to Aiolos promoter.
3.5. Ikaros and NFjB induce Aiolos expression
Since mutation of the NFjB- and Ikaros-binding sites in
Aiolos promoter abolished DNA binding and strongly reduces
luciferase activity and since ChIP experiments showed a direct
in vivo interaction of NFjB and Ikaros, we asked whether
NFjB and Ikaros overexpression would be able to induce
luciferase activity and Aiolos expression. Jurkat, Daudi and
U937 were transiently co-transfected with a mixture of
pGL3-175 and the either wild-type Ikaros (Ik2), the dominant
negative isoform of Ikaros (Ik8) or wild-type NFjB. After
transfection, cells were analyzed for luciferase activity and
Aiolos expression (Fig. 7A).
Jurkat, U937 and Daudi cells transfected with Ik2 showed
higher luciferase activity than control cells transfected with
pGL3-175. Similar results were obtained when NFjB was
transfected, except for Jurkat cells. On the contrary, cells
transfected with the dominant negative Ik8 showed lower level
of luciferase activity compared to control pGL3-175 (Fig. 7A).
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expression in Jurkat, Daudi and U937 cells (Fig. 7A) while
overexpression of Ik8 inhibited Aiolos expression. Expression
of transiently transfected Ik2, Ik8 and NFjB was conﬁrmed
by direct comparison of protein levels in Ik2, Ik8 and NFjB
in PGL3-175 transfected cells. Concerning AP4, we are analyz-
ing more in detail the contribution of this transcription factor
to the control of Aiolos expression. Statistical analysis is
shown to demonstrate the signiﬁcance of the diﬀerences. Com-parison of pGL3-92 versus pGL3-basic vector did not show
signiﬁcant diﬀerences.
The role of Ikaros and NFjB in the control of Aiolos
expression was also tested in freshly isolated B and T cells. B
and T cells were transiently co-transfected with pGFP and
either Ik2, Ik8 or NFjB. After transfection, cells were ana-
lyzed for Aiolos expression. Interestingly, overexpression of
Ik2 and NFjB induces Aiolos expression in freshly isolated
B and T cells, while overexpression of the dominant negative
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1612 A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616Ik8 inhibits its expression (Fig. 7B). The expression of Ik2, Ik8
and NFjB was monitored by Western blot. As internal control
of transfection, we analyzed the GFP expression by FACS.
These results suggest that Ikaros and NFjB trans-activate
the Aiolos promoter and induce Aiolos expression in cell lines,
as well as in freshly isolated B and T cells.4. Discussion
For a more complete understanding of the regulation of
Aiolos expression, we cloned and characterized the promoterregion of human Aiolos gene. The isolated DNA fragment
contained part of the exon 1 and the 5 0 upstream region. We
showed that major regulatory elements, which control the acti-
vation of transcription, are located 175 bp upstream of the
ATG start codon in Jurkat and HEK293 cells and 370 bp up-
stream of the ATG in Daudi cells. Maximal transactivation of
the Aiolos promoter requires the NFjB, Ikaros and, probably
also, AP4 transcription factors as shown by luciferase activity
and ChIP experiments. The diﬀerent promoter activity, in the
diﬀerent cell lines, may imply that a functional interaction
occurs between these transcription factors. Alternatively, it
may imply a diﬀerent status of DNA methylation. We also
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cription factors in the control of Aiolos expression, showing
that both nuclear proteins are able to induce Aiolos expression
in cell lines, as well as in freshly isolated B and T cells.
The DNA-binding potential of Ikaros, AP4 and NFjB was
examined by EMSA. The retarded bands were speciﬁc since ex-
cess of unlabeled Ikaros, NFjB and AP4 oligonucleotides
inhibited formation of the complexes whereas oligonucleotides
with mutated binding sites did not. In addition, the speciﬁcity
of bound proteins was conﬁrmed by supershift using speciﬁc
antibodies. In addition, mutation of NFjB-, AP4- and Ika-
ros-binding sites diminished basal promoter activity. Finally,
in vivo binding of Ikaros and moderated binding of AP4 and
NFjB was also identiﬁed by ChIP assay. In the Aiolos pro-
moter, one of the putative NFjB-binding sites overlaps with
an Ikaros-binding site. Similarly, in the e promoter, one of
the putative Ikaros-binding elements overlaps with a STAT6
binding site and two others with NFjB-binding sites. Using
the ChIP assay, we showed that NFjB, AP4 and Ikaros specif-
ically bind to the Aiolos promoter in Daudi, Jurkat and U937
cells but not in HEK293 cells in vivo, although the binding of
AP4 and NFjB is moderated. It is interesting to notice the dif-
ference between the in vitro (luciferase) and in vivo (ChIP) re-
sults in HEK293 and U937 cells: while we were able to detectluciferase activity in both cell lines, we were not able to detect
binding of Ikaros, NFjB and AP4 to the chromatin in
HEK293 cells and only moderated binding of Ikaros in
U937 cells. This could be explained by the possibility that a
multiprotein complex is formed between Ikaros, AP4 and/or
NFjB and other transcription factors and that HEK293 and
U937cells may lack unidentiﬁed binding factor(s) necessary
to form this complex. Alternatively, an inhibitory transcription
factor(s) binds to this site in HEK293 and U937 cells, prevent-
ing the binding of other transcription factors to this region.
Finally, we do not rule out the possibility that other trans-
cription factors, diﬀerent from Ikaros, NFjB and AP4 might
be suﬃcient to drive expression in HEK293 and U937cells.
A number of reports have identiﬁed the presence of Ikaros
binding sites in the promoters of a variety of lymphoid-speciﬁc
genes [21,28,29]. The Ikaros transcription factor was originally
isolated as a T cell speciﬁc gene encoding a zinc ﬁnger protein
that binds to an enhancer element in the CD3e gene [30]. More
recent studies have shown that this protein plays a key role in
the development of mature T and B lymphocytes and natural
killer cells. Moreover, Ikaros binds to the promoter region of
the human T cell speciﬁc gene that encodes the Grz B serine
protease, reinforcing the hypothesis of a pivotal role for this
transcription factor in lymphoid-speciﬁc gene expression [31].
Ikaros binding sites have also been detected in the promoter
of human STAT4 gene [32]. It has also been shown that the
T cell speciﬁc gene CD8a is an in vivo target of Ikaros, which
binds CD8 regulatory elements in vivo in a sequence-speciﬁc
manner. In addition, we do not rule out the possibility that
Aiolos auto-regulates its own expression.
It is believed that transcription factors are the ﬁnal pathway
driving diﬀerentiation. For instance, marginal zone B cells fail
to develop in the absence of Aiolos as well as in the absence of
NFjB p50 [4,33]. Finally, it is interesting to remark that NFjB
and AP4 binding sites are well conserved between human and
mouse Aiolos promoter.
Ikaros is known to act both as an activator and repressor of
transcription [34]. It has also been reported that Ikaros may
act together with other transcription factors to modulate pro-
moter activity [35]. For instance, IK2, an upstream stimulatory
factor, has been reported to synergize in transactivating the
promoter of the mouse opioid receptor gene.
The exact molecular mechanism by which AP4 inﬂuences
transcription is not known and in several cases AP4 has been
proposed to repress gene expression. For example, binding
of AP4 to the HIV-1 TATA elementin vitro was found to com-
pete for TATA-box binding protein binding to this element
and to inhibit in vitro transcription from the HIV-1 long termi-
nal repeat [36]. Within the late promoter region of SV40, AP4
appears to be involved in conferring signiﬁcant levels of nucle-
ase sensitivity, implicating AP4 in chromatin remodelling [37].
It has been proposed that AP4 might bind to its target se-
quence in the transcription factor Myc and Max, allowing
other transcription factors to bind in a co-operative manner
[37]. The role of AP4 in the control of Aiolos expression is
an ongoing project in our lab.
Four cell lines representative of lymphoid and non-lymphoid
cells with diﬀerential Aiolos expression were transfected with
luciferase expression vectors containing 5 0 deletions of the Aio-
los promoter. Further 5 0 deletions up to position 175 essen-
tially abolished the promoter activity, suggesting that the
core promoter might be located between the ATG and 175
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1614 A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616upstream of the ATG for Jurkat and HEK293 and 370 up-
stream of the ATG for Daudi cells. The promoter lacks TATA
and CAAT boxes, but a potential CpG islands was identiﬁed
between +13 and 306 bp, all characteristics of house keeping
genes. The transcription initiation site was located 153 bp up-
stream of the ATG start codon, as expected for eukaryotic
genes, where the transcription start is usually located 50–
150 bp upstream of the ATG. It is interesting to notice that
the promoter is cell-type independent. Results from luciferase
activity of the full length promoter, as well as the 5 0nested dele-
tions suggest the presence of negative regulatory elements in
the promoter, as well as upstream of the 3.9 kb fragment.It is clear from our results that Ikaros and NFjB have the
potential to stimulate Aiolos expression, suggesting that these
transcription factors may be considered as upstream Aiolos
eﬀectors. Interestingly, Ikaros knock out mice express Aiolos
[38]. This result is not in contradiction with our data since in
the mouse Aiolos promoter there is no binding site for Ikaros
transcription factor. But in the human context, Aiolos expres-
sion depends on Ikaros. Aiolos knock out mice lack marginal
zone B cells [4]. Similarly, this subset of peripheral B cells also
fails to emerge in mice lacking NFjB p50. However, we do not
exclude the hypothesis that Ikaros and NFjB may facilitate
other protein interactions rather than being activators per se.
A. Ghadiri et al. / FEBS Letters 581 (2007) 1605–1616 1615Taken together, our results show for the ﬁrst time that Ika-
ros and NFjB are important transcription factors involved in
the control of Aiolos expression. Our data provide a mechanis-
tic understanding of the regulation of Aiolos at transcriptional
level, providing a direct link between Ikaros/NFjB/ and Aio-
los. Further studies are in progress in order to determine
whether other members of the Ikaros family, as well as AP4,
are able to control Aiolos expression.
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